More than 100,000 people are receiving an experimental drug for severe anxiety and depression that has been approved by the Food and Drug Administration (FDA) in an effort to treat a rare form of epilepsy, according to an

published by Axios on Monday.

The drug, called diazepam, was approved in November 2016 by the FDA for the treatment of people with severe anxiety disorders that causes episodes of uncontrollable shaking.

While diazepamp is commonly used in a sedative-hypnotic state, the drug can also be used as a muscle relaxant, according the Axios article.

The study was conducted by researchers from the University of Pennsylvania’s Department of Psychiatry and Behavioral Sciences and Harvard Medical School and was published in the journal Archives of General Psychiatry.

According to the article, diazepams effectiveness in treating the severe anxiety disorder “is currently being evaluated.”

The drug’s manufacturer, Teva Pharmaceutical Industries, has said it expects to begin commercial production of diazepammos within the next two years.

The company said in a statement to Axios that the study was “conducted in a non-clinical setting and is not intended to diagnose, treat, or cure any disease or condition.”

According to Axs, Tevasdams efficacy in treating anxiety is currently being assessed.

The research also involved a collaboration between Penn and Harvard’s Departments of Psychiatry, Pharmacology and Behavioral Science, as well as the University at Buffalo and the National Institute on Drug Abuse.

Back To Top